Pandemics/Epidemics (Free)
Search All Applications in Pandemics/Epidemics (Free)
Application US20200308232
Published 2020-10-01
Coronaviruses Epitope-based Vaccines
Provided are polypeptides derived from the coronaviruses (CoVs) Spike protein (S) characterized by high affinity and specificity the S receptor and its neutralizing antibodies. Further provided are compositions and vaccines, and vaccine-based therapies targeting CoVs, and SARS and MERS viruses in particular.
Much More than Average Length Specification
View the Patent Matrix® Diagram to Explore the Claim Relationships
USPTO Full Text Publication >
- 1. A polypeptide comprising an amino acid sequence of at least one reconstituted Receptor Binding Motif (RBM) of a viral Spike protein or of any fragment thereof, wherein said reconstituted RBM comprises at least one linker and at least one fragment of the native RBM, said native RBM is a 30 to 200 amino acid sequence comprised within the Receptor Binding Domain (RBD) of said Spike protein forming a binding interface that interacts with the viral receptor.
- 12. A method for preventing, inhibiting, reducing, eliminating, protecting or delaying the onset of an infection or an infectious clinical condition caused by a viral pathogen, or of inducing an immune response against a viral pathogen in a subject in need thereof, the method comprising the step of administrating to said subject an effective amount of at least one polypeptide comprising an amino acid sequence of at least one reconstituted RBM of a viral Spike protein or of any fragment thereof, any derivative, enantiomer, fusion protein, conjugate or polyvalent dendrimer thereof or of any composition or vaccine comprising the same, wherein said reconstituted RBM comprises at least one linker and at least one fragment of the native RBM, said native RBM is a 30 to 200 amino acid sequence comprised within the RBD of said Spike protein forming a binding interface that interacts with the viral receptor.
- 15. A method for the preparation of a functional reconstituted RBM of a viral Spike protein, said method comprises the step of:
a) screening a conformer library of RBMs of said viral Spike protein with a binding molecule, wherein said library comprising plurality of bacteriophages, each expressing a reconstituted RBM comprising an amino acid sequence of at least one fragment of an RBM of a viral Spike protein and at least one exogenous combinatorial linker; and b) identifying and producing reconstituted RBM peptides which bind at least one of said binding molecule/s.
